WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Neurocrine Biosciences revenue was $2.36B for the trailing 12 months ending Dec 31, 2024, with 32.8% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $627.7M, up 0.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NBIX annual revenue was $2.4B, with 24.8% growth year-over-year.

NBIX past revenue growth

How has NBIX's revenue growth performed historically?

Company
24.81%
Industry
10.4%
Market
20.87%
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBIX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBIX revenue history

Current Revenue
$2.4B
Current Earnings
$341.3M
Current Profit Margin
14.5%

Be the first to know when NBIX announces revenue.

NBIX Revenue History By Year

NBIX Yearly RevenueNBIX RevenueNBIX ChangeNBIX Revenue Growth
2024-12-31$2.36B$468.20M+24.81%
2023-12-31$1.89B$398.40M+26.76%
2022-12-31$1.49B$355.20M+31.34%
2021-12-31$1.13B$87.60M+8.38%
2020-12-31$1.05B$257.80M+32.71%
2019-12-31$788.10M$336.90M+74.67%
2018-12-31$451.20M$289.57M+179.16%
2017-12-31$161.63M$146.63M+977.51%
2016-12-31$15.00M-$4.77M-24.12%
2015-12-31$19.77MN/AN/A
2014-12-31$0.00-$2.92M-100.00%
2013-12-31$2.92M-$50.22M-94.51%
2012-12-31$53.14M-$24.27M-31.36%
2011-12-31$77.41M$43.91M+131.08%
2010-12-31$33.50M$30.55M+1,034.47%
2009-12-31$2.95M-$1.02M-25.71%
2008-12-31$3.98M$2.75M+224.75%
2007-12-31$1.22M-$38.01M-96.88%
2006-12-31$39.23M-$84.66M-68.33%
2005-12-31$123.89M$38.71M+45.45%
2004-12-31$85.18M-$53.90M-38.76%
2003-12-31$139.08M$121.03M+670.73%
2002-12-31$18.05M-$23.20M-56.25%
2001-12-31$41.24M$26.65M+182.71%
2000-12-31$14.59M-$2.20M-13.12%
1999-12-31$16.79M$754.00k+4.70%
1998-12-31$16.04M-$10.11M-38.66%
1997-12-31$26.14M$6.93M+36.05%
1996-12-31$19.22M$13.11M+214.72%
1995-12-31$6.11M$5.94M+3,679.88%
1994-12-31$161.53kN/AN/A

1 of 3

Neurocrine Biosciences Revenue FAQ

What was NBIX's revenue last quarter?

On Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2024 revenue of $627.70 million up 21.84% year over year. In the same quarter last year, Neurocrine Biosciences's revenue was $515.20 million.

What was Neurocrine Biosciences's revenue in 2024?

Neurocrine Biosciences's annual revenue for the twelve months ending Dec 31, 2024 was $2.36 billion, a 24.81% increase year over year.

How much does Neurocrine Biosciences make in a day?

Based on Neurocrine Biosciences annual revenue for the past five years, NBIX makes an average of $4,334,520.55 per day.

What was Neurocrine Biosciences's annual revenue growth in the past year?

As of Q2 2025, Neurocrine Biosciences's revenue has grown 24.81% year over year. This is 14.41 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.4%. Neurocrine Biosciences's revenue in the past year totaled $2.36 billion.

How much does Neurocrine Biosciences make in a year?

Neurocrine Biosciences's revenue by year for the past five years is:
  • Neurocrine Biosciences's revenue for the twelve months ending Dec 31, 2024 was $2.36 billion, a 24.81% increase year over year.
  • Neurocrine Biosciences's annual revenue for Dec 31, 2023 was $1.89 billion, a 26.76% increase from 2022.
  • Neurocrine Biosciences's annual revenue for 2022 was $1.49 billion, a 31.34% increase from 2021.
  • Neurocrine Biosciences's annual revenue for 2021 was $1.13 billion, a 8.38% increase from 2020.
  • Neurocrine Biosciences's annual revenue for 2020 was $1.05 billion, a 32.71% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.